Market Share | Enzalutamide + ADT, % | Apalutamide + ADT, % | Bicalutamide + ADT, % | ADT, % |
---|---|---|---|---|
Without enzalutamide | ||||
Year 1 | 0.0 | 5.7 | 28.5 | 65.8 |
Year 2 | 0.0 | 16.0 | 25.4 | 58.6 |
Year 3 | 0.0 | 27.0 | 22.1 | 50.9 |
With enzalutamide | ||||
Year 1 | 5.7 | 5.4 | 26.9 | 62.0 |
Year 2 | 15.9 | 13.5 | 21.4 | 49.3 |
Year 3 | 25.8 | 20.0 | 16.4 | 37.8 |
ADT = androgen deprivation therapy.